AbbVie Pledges $100 Billion for US Investment and Manufacturing Growth

AbbVie is stepping up its commitment to the United States with a major investment pledge tied to a broad agreement with the US government. The Chicago-based biopharmaceutical company has agreed to invest a total of $100 billion in research, development and manufacturing projects across the country over the next decade. This pledge comes as part of a three year deal with the administration that also involves lowering certain Medicaid drug prices and securing exemptions from tariffs and future pricing mandates.

The investment is set to support expanded US-based R&D efforts, boost manufacturing capacity and enhance direct-to-patient drug availability through government channels. The move follows a trend among large pharma firms to strengthen domestic operations amid changing trade and pricing policies. AbbVie has also previously announced substantial capital commitments to expand active pharmaceutical ingredient and other manufacturing capabilities in multiple states, reinforcing its long-term presence in the US life sciences sector. The strategy is expected to support innovation, create jobs and improve access to medicines for patients across the country.